Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemdisiran and eculizumab dose-ranging study for paroxysmal nocturnal haemoglobinuria
ISRCTN31882639Phase 2Terminated
- Sponsor
- University of Leeds
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 2, open-label trial of cemdisiran and eculizumab in paroxysmal nocturnal hemoglobinuria (PNH) (4 cohorts), sponsored by University of Leeds. Primary endpoint: Disease control up to 8 weeks. Started Apr 2020; status: terminated.
02
Drugs
cemdisiraneculizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on ISRCTN31882639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN31882639.